EFFECT OF pH, SELECTED CYCLODEXTRINS AND COMPLEXATION METHODS ON THE SOLUBILITY OF LORNOXICAM
Keywords:
Lornoxicam, pH, Solubility, Cyclodextrins, Complexation methods, DissolutionAbstract
Objective: The objective of the present study is to investigate the effect of pH, selected cyclodextrins and methods of complexation on the solubility of lornoxicam.
Methods: Phase solubility studies were carried out according to Higuchi and Connors. Inclusion complexes of lornoxicam were prepared by different methods like kneading, ultrasoncation, spray drying along with the physical mixtures using β cyclodextrin and hydroxypropyl β cyclodextrins.
Results: Lornoxicam being weakly acidic drug showed extremely low solubility in the acidic medium (pH 1.2) and poor solubility in water. The solubility of the drug increased as the pH of the medium was subsequently increased up to 7.4 and a drastic increase in solubility perhaps several hundred folds was observed with the alkaline phosphate buffer (pH 10.0). Phase solubility studies revealed that, hydroxypropyl β cyclodextrin (HP β CD) up to the concentration of 20 mM showed a linear increase in solubility of lornoxicam whereas the solubility of lornoxicam was increased up to β cyclodextrin (β CD) concentration of 14 mM and beyond that the solubility of the drug reduced probably due to precipitation of the complexes. The stability constant (Ks) was found to be 378.55 M-1 and 867.262 M-1 for β CD and HP β CD respectively. Inclusion complexes of lornoxicam with cyclodextrins were prepared employing different methods and the effect of complexation methods on the dissolution of lornoxicam was studied. Dissolution studies revealed that, irrespective of the cyclodextrins used (β CD and HP β CD), highest drug release rate was observed from the spray dried products compared to those prepared by kneading and ultrasonication methods. Inclusion complexes prepared using HP β CD showed higher drug release compared to those prepared using β CD.
Conclusion: The study demonstrated the distinctive pH dependent of solubility of lornoxicam and also showed that cyclodextrins especially HP β CD can be utilized to improve the solubility of lornoxicam.
Downloads
References
Deepak Bahl, Robin H Bogner. Amorphization Alone Does Not Account for the Enhancement of Solubility of Drug Co-ground with Silicate:The Case of Indomethacin. AAPS Pharm Sci Tech 2008;9(1).
Prajapati BG, Patel MM. Conventional and alternative pharmaceutical methods to improve oral bioavailability of lipophilic drugs. Asian J Pharm 2007;1:1–8.
Rawlinson CF, Adrian C, Williams AC, Timmins P, Grimsey I. Polymer mediated disruption of drug crystallinity. Int J Pharm 2007;336:42–8.
Van de Waterbeemd H. The fundamental variables of the biopharmaceutics classification system(BCS):a commentary. Eur J Pharm Sci 1998;7:1–3.
Medhi B, Patyar S, Wadha S, Prasad Byrav DS. Lornoxicam:a newer NSAID. IJPMR 2009;20 (1):27-31.
Maryadele JO Neil. The Merck Index:An Encyclopedia of Chemical, Drug’s and Biologicals, 14 ed. Merck Research Lab, Division of Merck and co. Inc., Whitehouse Station, NJ;2001. p.610
Homdrum EM, Likar R, Nell G. Xefo® Rapid:a novel effective tool for pain treatment. Eur Surg 2006;38:342–52.
Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996;23:1605–11.
Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 1997;25:3–14.
Riekes MK, Tagliari MP, Granda A, Kuminek G, Silva MA, Stulzer HK. Enhanced solubility and dissolutionrate of amiodarone by complexation with β-cyclodextrin through different methods. Materials Science and Engineering C 2010;30:1008-13.
Lu Z, Cheng B, Hu Y, Zhang Y, Zou Y. Complexation of resveratrol with cyclodextrins:Solubility and antioxidant activity. Food Chemistry 2009;113:17–20.
Amidon Gl, Jinno J, Man Oh D, Crison JR. Dissolution of ionizable water-insoluble drugs:The combined effect of ph and surfactant. J Pharm Sci 2000;89 (2):268-74.
Bhise SD. Effect of Hydroxypropyl β-Cyclodextrin Inclusion Complexation on Solubility of Fenofibrate. Int J of Res in Pharm and Biomedical Sci 2011;2 (2):596-604.
Ghodke DS, Nakhat PD, Yeole PG, Naikwade NS, Magdum CS, Shah RR. Preparation and characterization of domperidone inclusion complexes with cyclodextrin:Influence of preparation method. Iranian J of Pharm Res 2009;8 (3):145-51.
Chowdary KPR, Sekuboyina VS. Influence of Hydrophilic Polymers on Celecoxib Complexation With Hydroxypropyl β-Cyclodextrin. AAPS Pharm Sci Tech 2006;7 (3) Article 79.
Abhurahma MH, Hamza YE. Design and in vitro evaluation of novel sustained release double layer tablets of lornoxicam:utility of cyclodextrin and xanthan gum combination. AAPs Pharma Sci Tech 2009;10 (4):1357-67.
Liu L, Zhu S. Preparation and characterization of inclusion complexes of prazosin hydrochloride with β cyclodextrin and hydroxypropyl β cyclodextrin. J of Pharm Biol Anal 2006;40:122–7.
Prajapati P, Vaghela V, Rawtani D, Patel H, Kubavat J, Baraiya D. Azeotropic mixture used for development and validation of lornoxicam in bulk and its tablet dosage form by spectrophotometric method. J Pharm Analysis 2012;2(4):306-09.
Chadha R, Kashid N, Saini A. Account of analytical techniques employed for the determination of thermodynamics of inclusion complexation of drugs with cyclodextrins. J Sci Ind Res 2004;63:211-29.